Alto Neuroscience, Inc. (NYSE:ANRO) Receives $20.00 Consensus Target Price from Analysts

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have been given a consensus recommendation of “Moderate Buy” by the eight analysts that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $20.00.

A number of research firms have commented on ANRO. Rodman & Renshaw lowered shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 23rd. Stifel Nicolaus lowered their price target on Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. William Blair reaffirmed an “outperform” rating on shares of Alto Neuroscience in a report on Tuesday, September 10th. Robert W. Baird lowered their target price on Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Finally, RODMAN&RENSHAW lowered shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd.

Hedge Funds Weigh In On Alto Neuroscience

A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. bought a new stake in Alto Neuroscience during the first quarter worth about $8,233,000. Price T Rowe Associates Inc. MD acquired a new position in shares of Alto Neuroscience in the 1st quarter valued at about $9,788,000. Bowie Capital Management LLC acquired a new position in shares of Alto Neuroscience during the 2nd quarter valued at $462,000. TD Asset Management Inc acquired a new stake in Alto Neuroscience in the second quarter valued at approximately $928,000. Finally, Zimmer Partners LP acquired a new stake in shares of Alto Neuroscience in the 1st quarter worth about $1,151,000.

Alto Neuroscience Stock Down 4.7 %

Shares of ANRO opened at $4.27 on Monday. Alto Neuroscience has a 1-year low of $3.61 and a 1-year high of $24.00. The firm has a 50 day simple moving average of $9.32 and a 200-day simple moving average of $11.13. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.05. Analysts anticipate that Alto Neuroscience will post -2.6 earnings per share for the current year.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.